X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8423) 8423
Book Chapter (44) 44
Publication (20) 20
Dissertation (19) 19
Conference Proceeding (6) 6
Magazine Article (2) 2
Book / eBook (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
everolimus (6645) 6645
humans (5742) 5742
female (3261) 3261
male (3025) 3025
sirolimus - analogs & derivatives (2814) 2814
middle aged (2458) 2458
oncology (2280) 2280
aged (2025) 2025
treatment outcome (1928) 1928
cardiac & cardiovascular systems (1399) 1399
adult (1342) 1342
sirolimus - therapeutic use (1327) 1327
cancer (1212) 1212
drug-eluting stents (1199) 1199
sirolimus - administration & dosage (1185) 1185
rapamycin (1086) 1086
transplantation (1079) 1079
sirolimus (1007) 1007
surgery (974) 974
animals (960) 960
immunosuppressive agents - therapeutic use (943) 943
tor serine-threonine kinases - antagonists & inhibitors (931) 931
antineoplastic agents - therapeutic use (899) 899
care and treatment (864) 864
mtor (837) 837
mammalian target (831) 831
time factors (808) 808
sirolimus - pharmacology (739) 739
sunitinib (736) 736
everolimus - administration & dosage (709) 709
efficacy (706) 706
analysis (699) 699
metastasis (693) 693
therapy (652) 652
follow-up studies (649) 649
pharmacology & pharmacy (648) 648
risk factors (648) 648
everolimus - therapeutic use (645) 645
survival (623) 623
tumors (623) 623
carcinoma, renal cell - drug therapy (617) 617
sirolimus - adverse effects (615) 615
kidney neoplasms - drug therapy (611) 611
percutaneous coronary intervention (606) 606
prospective studies (595) 595
trial (593) 593
retrospective studies (589) 589
thrombosis (580) 580
stents (559) 559
angiogenesis inhibitors (555) 555
prosthesis design (550) 550
stent (527) 527
immunosuppressive agents - administration & dosage (521) 521
immunology (511) 511
medicine & public health (503) 503
abridged index medicus (493) 493
chemotherapy (493) 493
patients (488) 488
research (486) 486
aged, 80 and over (483) 483
clinical trials (483) 483
cell line, tumor (476) 476
prognosis (474) 474
cyclosporine (467) 467
antineoplastic combined chemotherapy protocols - therapeutic use (466) 466
tor serine-threonine kinases - metabolism (463) 463
immunosuppressive agents - adverse effects (462) 462
coronary artery disease - therapy (459) 459
interferon-alpha (457) 457
breast cancer (445) 445
renal cell carcinoma (444) 444
tacrolimus (444) 444
double-blind (443) 443
kidney transplantation (442) 442
urology & nephrology (441) 441
implantation (438) 438
safety (437) 437
absorbable implants (432) 432
coronary angiography (431) 431
sorafenib (429) 429
mice (427) 427
immunosuppressive agents - pharmacology (411) 411
health aspects (406) 406
disease-free survival (405) 405
expression (401) 401
outcomes (397) 397
temsirolimus (392) 392
cardiovascular agents - administration & dosage (385) 385
drug therapy (380) 380
kidney neoplasms - pathology (374) 374
mtor inhibitors (370) 370
drug therapy, combination (365) 365
multicenter (362) 362
antineoplastic agents - pharmacology (353) 353
everolimus - adverse effects (352) 352
everolimus - pharmacology (352) 352
immunotherapy (352) 352
signal transduction - drug effects (352) 352
targeted therapy (351) 351
follow-up (347) 347
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8179) 8179
French (117) 117
Japanese (105) 105
German (88) 88
Spanish (67) 67
Russian (44) 44
Chinese (13) 13
Portuguese (12) 12
Italian (11) 11
Hungarian (9) 9
Korean (9) 9
Polish (8) 8
Czech (7) 7
Norwegian (3) 3
Turkish (3) 3
Dutch (2) 2
Slovenian (2) 2
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The journal of clinical endocrinology and metabolism, ISSN 0021-972X, 2017, Volume 102, Issue 2, pp. 698 - 707
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2017, Volume 35, Issue 34, pp. 3851 - 3858
Purpose Combination treatment with immune checkpoint inhibitors has shown enhanced antitumor activity compared with monotherapy in tumor types such as... 
EVEROLIMUS | ONCOLOGY | Index Medicus
Journal Article
Journal Article
European Urology, ISSN 0302-2838, 2017, Volume 72, Issue 6, pp. 962 - 971
Journal Article
Journal Article
Clinical cancer research, ISSN 1557-3265, 2016, Volume 22, Issue 22, pp. 5461 - 5471
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 2010, Volume 120, Issue 8, pp. 2858 - 2866
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 2/2018, Volume 81, Issue 2, pp. 347 - 354
Everolimus, an mTOR inhibitor, is active in refractory lymphomas. However, toxicity with flat dosing limits its usage. Speculatively,... 
Medicine & Public Health | Maintenance therapy | Oncology | Cancer Research | Pharmacology/Toxicology | Everolimus | B-cell malignancies | High dose cyclophosphamide | MAMMALIAN TARGET | 1ST-LINE TREATMENT | POSSIBLE MECHANISMS | INHIBITOR EVEROLIMUS | SINGLE-ARM | RENAL-CELL CARCINOMA | BREAST-CANCER | PHASE-II TRIAL | B-CELL | ONCOLOGY | RITUXIMAB | PHARMACOLOGY & PHARMACY | Cyclophosphamide - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Everolimus - administration & dosage | Antineoplastic Agents, Alkylating - administration & dosage | Everolimus - pharmacokinetics | Maintenance Chemotherapy - methods | Antineoplastic Agents - adverse effects | Adult | Everolimus - therapeutic use | Female | Drug Therapy, Combination | Lymphoma, B-Cell - drug therapy | Rituximab - adverse effects | Drug Administration Schedule | Lymphoma, Mantle-Cell - drug therapy | Treatment Outcome | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Transformation, Neoplastic | Leukemia, Lymphoid - drug therapy | Aged | Cohort Studies | Virus diseases | Antimitotic agents | Care and treatment | Pneumonia | Bacterial pneumonia | Lymphomas | Antineoplastic agents | Cancer | TOR protein | Therapy | Chronic lymphatic leukemia | Toxicity | Leukemia | Immunoglobulin G | Prophylaxis | Clinical trials | Rituximab | Pharmacology | Lymphatic leukemia | Dosage | Patients | Lymphoma | Serum levels | Cyclophosphamide | Consolidation | Lymphocytes B | Bacteria | B-cell lymphoma | Index Medicus
Journal Article
Cancer chemotherapy and pharmacology, ISSN 1432-0843, 2016, Volume 78, Issue 1, pp. 63 - 71
Journal Article
British journal of clinical pharmacology, ISSN 0306-5251, 2018, Volume 84, Issue 7, pp. 1575 - 1586
AIMS: Everolimus is a drug from the class of mammalian target of rapamycin inhibitors used for both immunosuppressant and oncological indications. We postulate... 
transplant | everolimus | cancer | nonmem | dose individualization | population pharmacokinetics | MAMMALIAN TARGET | THERAPY | PATHWAY | PHARMACOLOGY & PHARMACY | MTOR INHIBITORS | BLOOD | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Humans | Immunosuppressive Agents - pharmacokinetics | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Biological Availability | Male | Metabolic Clearance Rate | Everolimus - administration & dosage | Prednisolone - pharmacokinetics | Dose-Response Relationship, Drug | TOR Serine-Threonine Kinases - antagonists & inhibitors | Drug Therapy, Combination - adverse effects | Everolimus - pharmacokinetics | Everolimus - adverse effects | Adult | Female | Immunosuppressive Agents - administration & dosage | Tacrolimus - administration & dosage | Transplantation, Homologous - adverse effects | Drug Administration Schedule | Administration, Oral | Graft Rejection - prevention & control | Treatment Outcome | Tacrolimus - pharmacokinetics | Tacrolimus - adverse effects | Neoplasms - drug therapy | TOR Serine-Threonine Kinases - immunology | Drug Therapy, Combination - methods | Models, Biological | Neoplasms - immunology | Immunosuppressive Agents - adverse effects | Aged | Graft Rejection - immunology | Kidney Transplantation - adverse effects | Dosage and administration | Corticosteroids | Analysis | Prednisolone | Index Medicus | Original
Journal Article
PloS one, ISSN 1932-6203, 2016, Volume 11, Issue 6, p. e0158476
Journal Article